In vivo and in vitro effects of theophylline administration in recent onset, Type I, diabetic patients

A. Secchi, F. Crosti, M. R. Pastore, D. Pavoni, L. Falqui, P. Navone, A. E. Pontiroli, G. F. Ciboddo, C. Rugarli, G. Pozza

Research output: Contribution to journalArticle

Abstract

The metabolic and immunologic effects of short and long-term theophylline administration in recent onset Type I diabetic patients were studied in association with 'theophylline sensitivity' of lymphocytes in vitro as a marker of suppressive functions. Eighteen recent onset Type I diabetic patients entered the trial. Five were treated with theophylline (800 mg/d) for 1 mo (group A), 5 were treated with the theophylline (800 mg/d) for 8 mo (group B) and 8 were treated with placebo tablets (group C) in double blind. All patients were followed-up for 16-32 mo. A relationship between sensitivity to theophylline evaluated as inhibition of lymphocyte blastogenic response to Con A and the achievement of remission was observed. At the beginning of the study 8 patients were theophylline sensitive (Th+) (5 of group A, 2 of group B and 1 of group C) and 7 patients were theophylline resistant (Th-) (2 of group B and 5 of group C). Among the 9 Th+ patients, 6 reached the remission phase, while of the 7 Th- patients only 2 reached the remission phase. A high percentage (7/10) of the theophylline-treated patients achieved remission (4 of group A and 3 of group B), while only 3 of the 8 placebo treated patients achieved remission. In vivo theophylline effects were not improved by the longer (8 mo) treatment period. These results show that Th sensitivity in vitro can be considered a precocious marker of the clinical response to immunomodulating drugs in Type I diabetic patients. The favourable effects of theophylline treatment might provide the possibility of an immunomodulating drug free of side effects for recent onset Type I diabetes.

Original languageEnglish
Pages (from-to)113-118
Number of pages6
JournalDiabetes, Nutrition and Metabolism - Clinical and Experimental
Volume1
Issue number2
Publication statusPublished - 1988

Fingerprint

theophylline
Theophylline
remission
placebos
lymphocytes
Placebos
In Vitro Techniques
Lymphocytes
drugs
insulin-dependent diabetes mellitus
Drug-Related Side Effects and Adverse Reactions
Type 1 Diabetes Mellitus
Tablets
Biomarkers
adverse effects

ASJC Scopus subject areas

  • Food Science

Cite this

In vivo and in vitro effects of theophylline administration in recent onset, Type I, diabetic patients. / Secchi, A.; Crosti, F.; Pastore, M. R.; Pavoni, D.; Falqui, L.; Navone, P.; Pontiroli, A. E.; Ciboddo, G. F.; Rugarli, C.; Pozza, G.

In: Diabetes, Nutrition and Metabolism - Clinical and Experimental, Vol. 1, No. 2, 1988, p. 113-118.

Research output: Contribution to journalArticle

Secchi, A, Crosti, F, Pastore, MR, Pavoni, D, Falqui, L, Navone, P, Pontiroli, AE, Ciboddo, GF, Rugarli, C & Pozza, G 1988, 'In vivo and in vitro effects of theophylline administration in recent onset, Type I, diabetic patients', Diabetes, Nutrition and Metabolism - Clinical and Experimental, vol. 1, no. 2, pp. 113-118.
Secchi, A. ; Crosti, F. ; Pastore, M. R. ; Pavoni, D. ; Falqui, L. ; Navone, P. ; Pontiroli, A. E. ; Ciboddo, G. F. ; Rugarli, C. ; Pozza, G. / In vivo and in vitro effects of theophylline administration in recent onset, Type I, diabetic patients. In: Diabetes, Nutrition and Metabolism - Clinical and Experimental. 1988 ; Vol. 1, No. 2. pp. 113-118.
@article{0608e28f3307481db2b88db9f25e0be5,
title = "In vivo and in vitro effects of theophylline administration in recent onset, Type I, diabetic patients",
abstract = "The metabolic and immunologic effects of short and long-term theophylline administration in recent onset Type I diabetic patients were studied in association with 'theophylline sensitivity' of lymphocytes in vitro as a marker of suppressive functions. Eighteen recent onset Type I diabetic patients entered the trial. Five were treated with theophylline (800 mg/d) for 1 mo (group A), 5 were treated with the theophylline (800 mg/d) for 8 mo (group B) and 8 were treated with placebo tablets (group C) in double blind. All patients were followed-up for 16-32 mo. A relationship between sensitivity to theophylline evaluated as inhibition of lymphocyte blastogenic response to Con A and the achievement of remission was observed. At the beginning of the study 8 patients were theophylline sensitive (Th+) (5 of group A, 2 of group B and 1 of group C) and 7 patients were theophylline resistant (Th-) (2 of group B and 5 of group C). Among the 9 Th+ patients, 6 reached the remission phase, while of the 7 Th- patients only 2 reached the remission phase. A high percentage (7/10) of the theophylline-treated patients achieved remission (4 of group A and 3 of group B), while only 3 of the 8 placebo treated patients achieved remission. In vivo theophylline effects were not improved by the longer (8 mo) treatment period. These results show that Th sensitivity in vitro can be considered a precocious marker of the clinical response to immunomodulating drugs in Type I diabetic patients. The favourable effects of theophylline treatment might provide the possibility of an immunomodulating drug free of side effects for recent onset Type I diabetes.",
author = "A. Secchi and F. Crosti and Pastore, {M. R.} and D. Pavoni and L. Falqui and P. Navone and Pontiroli, {A. E.} and Ciboddo, {G. F.} and C. Rugarli and G. Pozza",
year = "1988",
language = "English",
volume = "1",
pages = "113--118",
journal = "Diabetes, Nutrition and Metabolism - Clinical and Experimental",
issn = "0394-3402",
publisher = "Editrice Kurtis s.r.l.",
number = "2",

}

TY - JOUR

T1 - In vivo and in vitro effects of theophylline administration in recent onset, Type I, diabetic patients

AU - Secchi, A.

AU - Crosti, F.

AU - Pastore, M. R.

AU - Pavoni, D.

AU - Falqui, L.

AU - Navone, P.

AU - Pontiroli, A. E.

AU - Ciboddo, G. F.

AU - Rugarli, C.

AU - Pozza, G.

PY - 1988

Y1 - 1988

N2 - The metabolic and immunologic effects of short and long-term theophylline administration in recent onset Type I diabetic patients were studied in association with 'theophylline sensitivity' of lymphocytes in vitro as a marker of suppressive functions. Eighteen recent onset Type I diabetic patients entered the trial. Five were treated with theophylline (800 mg/d) for 1 mo (group A), 5 were treated with the theophylline (800 mg/d) for 8 mo (group B) and 8 were treated with placebo tablets (group C) in double blind. All patients were followed-up for 16-32 mo. A relationship between sensitivity to theophylline evaluated as inhibition of lymphocyte blastogenic response to Con A and the achievement of remission was observed. At the beginning of the study 8 patients were theophylline sensitive (Th+) (5 of group A, 2 of group B and 1 of group C) and 7 patients were theophylline resistant (Th-) (2 of group B and 5 of group C). Among the 9 Th+ patients, 6 reached the remission phase, while of the 7 Th- patients only 2 reached the remission phase. A high percentage (7/10) of the theophylline-treated patients achieved remission (4 of group A and 3 of group B), while only 3 of the 8 placebo treated patients achieved remission. In vivo theophylline effects were not improved by the longer (8 mo) treatment period. These results show that Th sensitivity in vitro can be considered a precocious marker of the clinical response to immunomodulating drugs in Type I diabetic patients. The favourable effects of theophylline treatment might provide the possibility of an immunomodulating drug free of side effects for recent onset Type I diabetes.

AB - The metabolic and immunologic effects of short and long-term theophylline administration in recent onset Type I diabetic patients were studied in association with 'theophylline sensitivity' of lymphocytes in vitro as a marker of suppressive functions. Eighteen recent onset Type I diabetic patients entered the trial. Five were treated with theophylline (800 mg/d) for 1 mo (group A), 5 were treated with the theophylline (800 mg/d) for 8 mo (group B) and 8 were treated with placebo tablets (group C) in double blind. All patients were followed-up for 16-32 mo. A relationship between sensitivity to theophylline evaluated as inhibition of lymphocyte blastogenic response to Con A and the achievement of remission was observed. At the beginning of the study 8 patients were theophylline sensitive (Th+) (5 of group A, 2 of group B and 1 of group C) and 7 patients were theophylline resistant (Th-) (2 of group B and 5 of group C). Among the 9 Th+ patients, 6 reached the remission phase, while of the 7 Th- patients only 2 reached the remission phase. A high percentage (7/10) of the theophylline-treated patients achieved remission (4 of group A and 3 of group B), while only 3 of the 8 placebo treated patients achieved remission. In vivo theophylline effects were not improved by the longer (8 mo) treatment period. These results show that Th sensitivity in vitro can be considered a precocious marker of the clinical response to immunomodulating drugs in Type I diabetic patients. The favourable effects of theophylline treatment might provide the possibility of an immunomodulating drug free of side effects for recent onset Type I diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0024270053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024270053&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0024270053

VL - 1

SP - 113

EP - 118

JO - Diabetes, Nutrition and Metabolism - Clinical and Experimental

JF - Diabetes, Nutrition and Metabolism - Clinical and Experimental

SN - 0394-3402

IS - 2

ER -